Field-based evidence of fast and global increase of Plasmodium falciparum drug-resistance by DNA-microarrays and PCR/RFLP in Niger
© Ibrahim et al; licensee BioMed Central Ltd. 2009
Received: 01 August 2008
Accepted: 23 February 2009
Published: 23 February 2009
Over the last years, significant progress has been made in the comprehension of the molecular mechanism of malaria resistance to drugs. Together with in vivo tests, the molecular monitoring is now part of the survey strategy of the Plasmodium sensitivity. Currently, DNA-microarray analysis allows the simultaneous study of many single nucleotide polymorphisms (SNP) of Plasmodium isolates. In December 2005, the International Federation of the Red Cross distributed two million three hundred thousand long-lasting insecticide nets to pregnant women and mothers of under five years children in the whole Niger. Then, Niger adopted artemisinin-based combination therapy as first-line treatment.
Thirty four SNPs of pfcrt, pfdhfr, pfdhps, pfmdr and pfATPase were analysed by DNA-microarray and PCR/RFLP in two villages – Zindarou and Banizoumbou – with different durations of malaria transmission. The main objective of the study was to measure the dynamics of Plasmodium falciparum resistant strains and associated factors.
This study shows a global and clear increase of the drug-resistance associated molecular markers frequencies during a relatively short-time period of four years. Markers associated with resistance to chloroquine and sulphonamids were more frequently found in the short transmission zone than in the long transmission one. The pfcrt76T mutation is significantly more present at Banizoumbou than Zindarou (38.3% vs 25.2%, p = 0.013).
This work allowed the screening of several field strains for five SNPs of PfATPase6 gene. The pfATPase6S769N, candidate mutation of resistance to artemisinin was not found. However the pfATPsaeA623E mutation was found in 4.7% of samples.
A significant increase of several SNPs frequencies was highlighted over a four-year period. The polymorphism of five PfATPase6 gene SNPs was described. The global, large and fast increase of the molecular resistance is discussed in the context of current changes of health policy and malaria control in Niger.
Malaria drug resistance is a major world wide public health issue. If funding efficacious drugs is presently possible for many African countries, the future remains questionable. For many transmissible diseases, the efficacy of chemical treatment is a matter of time and resistant strains can emerge . If regularly monitoring the pattern of drug resistance is of prime importance, questioning the processes involved in the emergence of resistance and selection helps to define the treatment policy. Plasmodium falciparum has been shown to use several mechanisms for drug resistance. These last decades, the knowledge about molecular mechanisms of malaria drug resistance has significantly increased. Molecular surveys are now included in the P. falciparum sensitivity surveillance strategy promoted by the WHO, in association with in vivo tests. The resistance to chloroquine is linked to the pfcrtK76T mutation, a gene located on chromosome 7 , and clinical assays have confirmed this association [3, 4].
The dhfrS108N mutation, carried by chromosome 4, is the key mutation site for resistance to pryrimethamine. However, the mutations of the SNPs 51 and 59 modulate it. The triple mutation dhfrS108AN, dhfrC59R, dhfrN51I have been shown to be selected in failures of the sulphadoxine-pyrimethamine association (SP) [5, 6]. The pfdhps gene on chromosome 8 is coding for the dihydropteroate synthetase (pfdhps) and mutations of this gene are linked to sulphamid resistance. The dhpsS436A, dhpsA437G, dhpsK540E and dhpsA581G mutations have been described [4, 7]. The dhpsA437G, dhpsK540E double mutation or the pfdhpsS436A, dhpsA437G, dhpsK540E triple mutation are found linked with the higher resistance levels [5, 7].
The multi-drug resistance gene of P. falciparum, localized on chromosome 5, is coding for the P-glycoprotein. The pfmdrA86Y mutation is suspected to be linked with the cross-resistance to amodiaquine and chloroquine [8, 9]. The copy number of pfmdr gene is suspected to be associated to mefloquine resistance . The SERCA-pfATPase6 gene is a putative candidate to the artemisinin derivatives resistance. The pfATPase6S769N mutation has been described associated with artemether increased CI50 values in French Guyana . However, this mechanism does seem to be unique, since Plasmodium may develop artemisinin resistance without that mutation .
Usually, the PCR-RFLP is used to study these mutations. Even if robust and affordable for African malaria research centres, this method does not allow a high throughput screening of many mutations sites. The development of micro-array techniques offers the ability of such a screening of many isolates , including field-collected ones . So the monitoring of P. falciparum sensitivity to treatment survey can take benefit of this technique.
In Niger, malaria remains the main cause of morbidity and mortality with about 850,000 declared cases a year, an estimated incidence of 419/1,000 inhabitants and an estimated global fatality rate of 0.56%, reaching 20% in hospitalized patients .
However, Niger has entered in a very active phase of malaria control. A mass distribution of long-lasting insecticide-impregnated bed nets to mothers of children under five has been implemented in December 2005. Pregnant women benefit from intermittent preventive treatments with sulphadoxine-pyrimethamine (SP). Finally, Niger has adopted the use of artemisinin combination therapy (ACT) as first-line treatment of uncomplicated malaria cases. In this context, it is of prime importance to follow the sensitivity of P. falciparum strains to treatment, both old ones and new ones. Beside in vivo studies led by the National Malaria Control Programme (PNLP) and WHO-Niger , the CERMES has set up a molecular survey programme . Two molecular markers have been studied by par PCR-RFLP: pfcrt76 and pfdhfr108. In the Niger river valley, the prevalence of the pfcrt76T and dhfr108N mutations was respectively 50.8% and 57% in 2005 . In collaboration with the Institute Pasteur of Cambodia, some of the samples were tested with DNA-microarray dedicated to the detection of Single Nucleotide Polymorphisms (SNPs) associated with P. falciparum resistance [20, 14].
To explore the conditions of emergence and spread, the temporal evolution of molecular markers of P. falciparum drug resistance was studied in two Sahel villages between 2003 and 2006. Usual old drugs-chloroquine and pyrimethamine – were tracked by PfcrtK76T and pfdhfrS108N mutations by the microarray and PCR-RFLP methods, while other potential molecular markers from five genes, pfcrt, pfdhfr, pfdhps, pfmdr and pfATPase, were studied only by the microarray technique.
Materials and methods
Samples from asymptomatic P. falciparum carriers were tested from two villages (46 samples each). Patients were stratified by age (under 15 and over 15 years old) and by parasitaemia (46 patients presenting parasitaemia under 500 parasites and 46 over 500 parasites/μl). The two years of collection, 2003 and 2006, were equally distributed (46 patients sampled in 2003 and 46 in 2006). The collections were performed in October, at the end of the rainy seasons. These samples were tested by DNA micro-array technique, targeting the global temporal evolution between the two years 2003 and 2006 for five genes. These data were completed by testing of additional samples from the same two villages, respectively 250 and 245 samples in Zindarou and Banizoumbou, collected during the four years from 2003 to 2006. The aim of these extra materials was to see if the temporal trend had a continuous or a discontinuous pattern. These last samples were tested by PCR-RFLP for the only pfcrtK76T and the pfdhfrS108N mutations, which both presented the most evident temporal evolutions by DNA micro-array technique. The National Ethics Committee of Niger approved the study.
Blood slides and finger pricks on filter cards were performed in the field. Parasite carriage was assessed by microscopy after Giemsa staining. The parasitaemia threshold was established to 40 parasites/μl. DNA was extracted in 96 well-plates by resin method with Instagen. Briefly, red blood cells were discarded from filter cards after lysis with HBS1x/10% saponin (Hepes 100 mM, NaCl 1.4 M, KCl 100 mM) buffer then washed three times. Parasites were heated at 56°C then 90°C with 200μl of Instagen. Finally DNA was purified by centrifugation at 4,000 rpm for 20 mn.
The microarray method was used as described in Crameri et al . This method was performed at the Institute Pasteur of Cambodia. A total of 34 SNPs from five different genes (pfcrt, pfdhfr, pfdhps, pfmdr and pfATPase) were analysed by 34 SNPs. Decision values were determined by an algorithm including absolute signal and relative (green/red) values of optical densities . Control samples with known SNPs patterns were introduced in the assay.
The results were transferred to a database and analyzed by EPI-Info™ (Centers for Disease Control and Prevention). The mixed (wild + mutation) isolates were encoded as mutation. The bivariate analysis was performed with Epi-Info. Once found at p 0.20 significance threshold, the independence of factors (age, sex, parasitaemia, village and year) was tested by a conditional backward stepwise logistical regression model with molecular markers as dependant variables with the SPSS software (SPSS Inc., Chcago).
495 samples were tested by PCR/RFLP, among which 250 from Zindarou and 245 from Banizoumbou villages. 92 samples were tested by DNA-chips method with 46 samples from each village. The mean age was 11.26 yrs old (N = 587). The sex ratio (F/M) was 1.14 (N = 587). The mean geometrical mean of parasitaemia was 1.364 parasites by μl (N = 587).
Polymorphisms and prevalence of mutations
The data are presented gene by gene. The analysis was performed on data following quality criteria, i.e. above optical density thresholds.
Relative frequencies of polymorphic Pfrct gene SNPs according to villages, ages and years
Number of samples
Banizoumbou vs Zindarou
Adults vs under 15
2003 vs 2006
11.1% vs 9.5%
(p = 1.0)
22.2% vs 7.1%
(p = 0.084)
0.0% vs 21.4%
(p = 0.001)*
(p = 0.013)*
37.8% vs 31.5%
(p = 0.405)
20.0% vs 44.4%
(p = 0.013) *
15.6% vs 7.1%
(p = 0.317)
16.7% vs 10.1%
(p = 0.425)
2.2% vs 21.4%
(p = 0.006)
10.0% vs 10.8%
(p = 1.0)
25.0% vs 6.5%
(p = 0.053)
0.0% vs 19.5%
(p = 0.006)*
Relative frequencies of polymorphic Pfdhfr gene SNPs according to villages, ages and years
Number of samples
Banizoumbou vs Zindarou
Adults vs under 15
2003 vs 2006
22.7% vs 19.5%
(p = 0.717)
23.5% vs 20.6%
(p = 0.75)
9.3% vs 33,3%
(p = 0.008)
80.0% vs 73.1%
(p = 0.541)
77.8% vs 76.6%
(p = 0.939)
73.9% vs 78,8%
(p = 0.671)
58.4% vs 46.9%
(p = 0.057)
40.0% vs 56.1%
(p = 0.058)*
21.7% vs 45.7%
(p = 0.015)*
20.0% vs 26.9%
(p = 0.541)
44.4% vs 19.1%
(p = 0.189)
4.3% vs 36.4%
(p = 0.008)*
12.2% vs 10.0%
(p = 1.0)
14.3% vs 10.4%
(p = 0.65)
4.7% vs 18.4%
(p = 0.076)
40.0% vs 19.2%
(p = 0.092)
33.3% vs 29.8%
(p = 1.0)
7.4% vs 39.4%
(p = 0.139)
13.3% vs 11.5%
(p = 1.0)
22.2% vs 18.2%
(p = 0.312)
0% vs 21.2%
(p = 0.034)
Relative frequencies of polymorphic Pfdhps gene SNPs according to villages, ages and years
Number of samples
Banizoumbou vs Zindarou
Adults vs under 15
2003 vs 2006
73.8% vs 69.0%
(p = 0.629)
52.9% vs 76.1%
(p = 0.059)
76.2% vs 66.7%
(p = 0.334)
71.0% vs 77.8%
(p = 0.743)
50.0% vs 79.5%
(p = 0.06)
77.3% vs 70.4%
(p = 0.586)
19.0% vs 0.0%
(p = 0.006)*
12.5% vs 9.5%
(p = 0.661)
0.0% vs 20.5%
(p = 0.002)*
95.6% vs 100.0%
(p = 0.494)
100.0% vs 97.1%
(p = 1.0)
100.0% vs 95.5%
(p = 0.236)
61.3% vs 61.1%
(p = 0.99)
30.0% vs 69.2%
(p = 0.033)
68.2% vs 55.6%
(p = 0.367)
436, 437, 581
16.1% vs 0.0%
(p = 0.146)
10.0% vs 10.5%
(p = 1.0)
0.0% vs 19.2%
(p = 0.054)
436, 437, 640
56.7% vs 61.1%
(p = 0.762)
30.0% vs 65.8%
(p = 0.07)*
50.0% vs 68.2%
(p = 0.203)
436, 437,581, 640
16.7% vs 0.0%
(p = 0.143)
10.0% vs 10.8%
(p = 1.0)
0.0% vs 20.0%
(p = 0.052)
Relative frequencies of polymorphic Pfmdr and pfATPase genes SNPs according to villages, ages and years
Number of samples
Banizoumbou vs Zindarou
Adults vs under 15
2003 vs 2006
13.6% vs 21.4%
(p = 0.341)
5.9% vs 20.3%
(p = 0.284)
22.7% vs 11.9%
(p = 0.186)
6.7% vs 2.4%
(p = 0.618)
12.5% vs 2.9%
(p = 0.156)
0.0% vs 9.8%
(p = 0.048)*
6.8% vs 2.4%
(p = 0.616)
5.6% vs 4.4%
(p = 1.0)
0.0% vs 9.5%
(p = 0.053)
Only the 623 codon of the pfATPase6 gene was polymorphic and the mutation was found in 4.7% (4/86) of the cases (Table 4). The pfATPaseS769N mutation was not found as were not the others targeted mutations at the 538, 574, and 683 codons.
Only three strains presented both a mutation at pfmdr and pfcrt genes (two with pfmdr86 and pfcrt76 and one with pfmdr1034 and pfcrt76). All these three isolates came from 2006 samples.
Considering the pfdhfr and pfdhps genes, targeting the SP efficacy, one strain presented both the triple 51, 59 and 108 pfdhfr mutation and the quadruple 436–437–581 and 640 pfdhps mutation. Among the triple pfdhfr mutants, seven isolates presented at least one mutation at the pfdhps gene; all of them were collected in 2006.
Variations according to time
For the pfdhfr gene, the mutations at positions 51 (p = 0.008) and 108 (p = 0.015) have also significantly an increased prevalence between the two years 2003 and 2006. The prevalence of the pfdhfrS108N mutation increased significantly from year to year (Kruskall-Wallis df 3, p < 0.001) except between 2005 and 2006 where the prevalence decreased significantly (p < 0.001). Between 2003 and 2006, the prevalence of the 51/59 double mutation increased significantly from 4.3% to 36.4% (p = 0.008) as the 51/59/108 triple mutation from 0% to 21.2% (p = 0.034) (Table 2).
For the two pfdhps and pfmdr genes presenting respectively four and two polymorphic codons, only the prevalences of pfdhpsA581G (0% vs. 20.5%, p = 0.002) and pfmdrS1034C (0% vs 9.8%, p = 0.048) mutations have significantly increased between 2003 and 2006. All samples with the pfATPaseAla623Glu mutation were found during 2006 (p = 0.053). Globally, among the all 15 polymorphic codons, the prevalence of nine were significantly increasing between the 2003 and 2006 years, when no mutation prevalence was significantly decreasing.
Variation according to the villages (malaria transmission length)
Globally, the pfcrt76T mutation was significantly more present at Banizoumbou than Zindarou (38.3% vs. 25.2%, p = 0.013) (Table 1). The other polymorphic mutation positions (74, 97, 220 and 371) did not differ between locations. For the pfdhfr gene, the 108 (58.4% vs. 46.9%), mutation and the 108/59 (40.0% vs. 19.2%) double mutation had the same trend as pfcrt – i.e. higher in Banizoumbou – but none significantly. For the pfdhps gene, only the pfdhpsA581G mutation was significantly different in the two villages, being present only at Banizoumbou (19% vs. 0%, p = 0.006). The frequencies of mutations of the two genes pfmdr and pfATPase were not different in the two villages.
Variation according to host factor (age, sex, parasitaemia)
The only significant link found was the under 15 years age more often associated with the double pfdhps 436–437 mutation (Table 3). No link was found between the studied mutations, parasitaemia or sex.
The data show a global and significant increase of the drug resistance associated molecular markers frequencies. This increase concerns several (9 out of 15) polymorphic molecular markers linked to different metabolic pathways. The study covered a relatively short-time period of four years, showing a mean doubling of frequencies of mutations highly linked to resistance, such as pfcrt76 and pfhdfr108. The dynamics highlighted here appear to be fast, global and intense.
These data add arguments to the debate about the links between transmission and resistance [23, 24]. On the one hand, Talisuna et al in Uganda  have shown higher levels of resistance to chloroquine and SP in zones of higher transmission intensity. On the other hand, history shows that chloroquine resistance emerged first in low transmission zones and that antifolate resistance has increased more rapidly in low transmission areas . Theoretical models support the view that the spread of resistance in low transmission area is favoured either by the high selfing-rate  or by intra-host competition . Others models  have shown that the transmission rate may not be the main force driving the resistance spread, which may rather be led by drug pressure or immunity.
However, field data are scarce. Here, the mutations tended to be more frequent in the village with the shorter malaria season: Banizoumbou. This was verified for the pfcrtK76T mutation. It has to be noted that the two villages share very comparable social patterns (distance from main road, health facilities, ethnicity, millet-based economy), but differ in their water bodies – ie Anopheles breeding sites – duration times. This corroborates the hypothesis that the resistance could spread more easily in low-transmission zones. The field data presented here correspond to one of the most restricted spatial scale ever described for this effect: these two villages are only 30 km distant. History has shown at the worldwide-scale that resistance emerged from low transmission area (Amazonia, South East Asia), and this may be verified at a very local scale. The same tendency for pfdhfr and others markers seems to give a global value to the processes involved in the spread of resistance.
The frequencies of mutation tended to be higher among the younger parasite carriers. However, this relation was significant only for the dhps436/437 double mutation. As the immunity or the drug pressure may be involved, the study was not designed to answer these issues. The global prevalence of pfcrtK76T, 32.4%, was lower than in many published works performed in Africa , but not so far from regional data [3, 28]. In comparison with local data this prevalence was different from the one observed in hospitalized urban population recorded in 2003: Ibrahim et al found respective prevalence of pfcrtK76T and pfdhfrS108N mutations of 45.4% and 61.9% . Later in 2005  among patients attending rural health centres, the prevalence was closer to the 2005 values: 50.8% for pfcrt76 and 57.7% for dhfr108. However, the present work was targeting asymptomatic carriers in a rural zone, not patients attending to clinics or hospitals, and the drug pressure appears to be different in those different populations.
Recent works have studied the ATPase6 gene and specially the pfATPase6S769N mutation as a candidate marker for artemisinin resistance . For first time, several field strains could be screened for five SNPs of PfATPase6 gene. The pfATPase6S769N mutation was not found. However, the pfATPaseA623E mutation was found in 4.7% of samples. The more precise sequence data for this gene are presented elsewhere .
The respective factors driving the emergence and spread of malaria drug resistance are not well known. Drug pressure, clonality of infections, pharmacokinetics, human migrations, immunity, fitness of parasites and transmission levels have all been suspected [24–27, 30, 31]. One interesting point of this work is the role of the intervention to block transmission. Two millions and three hundred thousands long-lasting insecticide-impregnated bed nets were distributed in December 2005. The bed nets reduce the lifespan of the vectors and the contact between human host and vector. This decreases the malaria transmission. Alifrangis et al have observed a significant decrease of molecular resistance to pryrimethamine after impregnated bed nets in Tanzania . On the other hand, a controled trial of the impact of impregnated bed nets in Ivory Coast found no significant difference in pfcrt, pfdhfr and pfdhps mutations prevalences between treated villages and negative controls [33, 34]. Diallo et al in Burkina Faso observed that impregnated curtains are not associated with an increase of molecular resistance or therapeutic failure in children under five years of age .
A decrease or stabilization of the molecular resistance has been shown between 2005 and 2006 for pfcrtK76T and pfdhfrS108N (Figure 2), when the trend is to a global increase during the 2003–2006 period. During this period, given the parasite carriage among children between two and five years of age, the malaria transmission in the two villages has decreased significantly (chi-square p < 0.0001), whether due or not to the impregnated bed nets distribution, from 56.5% (n = 255) in 2005 to 37.1% (n = 237) in 2006. What was observed in molecular markers then could be related either to a decrease of drug pressure or to a direct effect of transmission decrease on mutation carrying strains. A decrease of drug pressure cannot account for the pfdhfrS108N dynamics, when the SP is not often used in the study zone and rarely as the first-line treatment . Beside this drug pressure hypothesis, the decrease of resistant strains may be related to:
An absolute – i.e. in absence of drug pressure – weaker fitness of resistant strains in competition with wild strains during the transmission season: this is compatible with the observed higher frequency of resistant strains in low transmission area, where the competition between strains related to the chance of transmission events, is lower.
A best fitness of mutation carrying strains, when drugs are delivered during the malaria season, with a relative lower fitness of wild strains, especially at the end of the transmission season when the drug pressure is maxima. This effect is cumulative during the dry season, when there is no transmission and thus no competition with wild strains. So the resistance could favour the longer parasite carriage during the dry season, but not the competition with wild strains as the new transmission season begins. This theoretical view is in accordance of the observed decrease after bed net distribution by personal protection and decrease of drug pressure.
Whatever the processes involved, and taking in account the short duration time of the malaria transmission period in Sahel, the selective advantage kept all along the dry season by mutation carrying strains seems to be cumulative from year to year and tends to a global increase.
This work highlights a global increase of frequencies of mutation molecular markers linked to malaria drug resistance during a relatively short period of four years. Given the wide range of molecular markers studied by the DNA microarray method, the observed increase of several markers corresponds to different metabolic pathways. This reinforces the hypothesis of a global process involving transmission and fitness of mutation, rather than simultaneous drug pressures. In the context of new reinforcement of malaria control in Niger, based both on introduction of artemisinin-based combination therapy and vector control, the present data may be considered as baseline data for future drug resistance monitoring.
Thanks to the Banizoumbou and Zindarou inhabitants who participated to this work. We are grateful to the Ministry of Health and the National Malaria Control Program (PNLP). We are thankful to the technicians of the CERMES Parasitology Unit and the Institut Pasteur of Cambodia.
Field studies and sampling were funded by the WHO and the African Monsoon Multidisciplinary Analysis (AMMA). Based on a French initiative, AMMA was built by an international scientific group and is currently funded by a large number of agencies, especially from France, UK, US and Africa. It has been the beneficiary of a major financial contribution from the European Community's Sixth Framework Research Programme. Detailed information on scientific coordination and funding is available on the AMMA International web site http://www.amma-international.org.
DNA microarray tests were funded by the Institut Pasteur (Resmalchip European Community project, Fonds dédiés Parasitologie and ORA network project) and genotyping PCRs by the FSP/RAI 2001-168 project (French Ministry of Foreign Affairs).
- Baudon D, Robert V, Boudin C, Carnevale P, Gazin P: Moyens de lutte antiplasmodiale. Etudes médicales. 184: 147-164.Google Scholar
- Sidhu AB, Verdier-Pinard D, Fidock DA: Chloroquine resistance in P. falciparum malaria parasites conferred by pfcrt mutations. Science. 2002, 298: 210-3. 10.1126/science.1074045.PubMed CentralView ArticlePubMedGoogle Scholar
- Djimdé A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourté Y, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV, Coulibaly D: A molecular marker for chloroquine resistant falciparum. NEJM. 2001, 344: 257-263. 10.1056/NEJM200101253440403.View ArticlePubMedGoogle Scholar
- OMS: Sensibilité de Plasmodium falciparum aux médicaments antipaludiques: 1996–2004. Rapport sur la surveillance globale 1996–2004. Suisse. 2005, 135-Google Scholar
- Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV: Molecular markers for failure of sulfadoxine-pyrimethamine and Chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 2002, 185: 380-388. 10.1086/338566.View ArticlePubMedGoogle Scholar
- Hyde JE: Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs. Microbes Infect. 2002, 4: 165-174. 10.1016/S1286-4579(01)01524-6.View ArticlePubMedGoogle Scholar
- Triglia T, Wang P, Sims P, Hyde J, Cowman AF: Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthetase in sulfadoxine-resistant malaria. EMBO J. 1998, 17: 3807-3815. 10.1093/emboj/17.14.3807.PubMed CentralView ArticlePubMedGoogle Scholar
- Foote SJ, Kyle DE, Martin SK, Odula AM, Forsyth K, Kemp DJ, Cowman AF: Several alleles of multidrug resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Nature. 1990, 345: 255-258. 10.1038/345255a0.View ArticlePubMedGoogle Scholar
- Foote SJ, Thompson JK, Cowman AF, Kemp DJ: Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum. Cell. 1989, 57: 921-930. 10.1016/0092-8674(89)90330-9.View ArticlePubMedGoogle Scholar
- Price R, Robinson G, Brockman A, Cowman A, Krishna S: Assessment of pfmdr 1 gene copy number by tandem competitive polymerase chain reaction. Mol Biochem Parasitol. 1997, 85: 161-169. 10.1016/S0166-6851(96)02822-8.View ArticlePubMedGoogle Scholar
- Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, Ekala MT, Bouchier C, Esterre P, Fandeur T, Mercereau-Puijalon O: Resistance of Plasmodium falciparum field isolated to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet. 2005, 366: 1960-1963. 10.1016/S0140-6736(05)67787-2.View ArticlePubMedGoogle Scholar
- Afonso A, Hunt P, Cheesman S, Alves AC, Cunha CV, do Rosario V, Cravo P: Malaria parasites can develop stable resistance to artemisine but lack mutation in genes ATPase, TCTP, MDR CG10. Antimicrob Agents Chemother. 2006, 50: 480-489. 10.1128/AAC.50.2.480-489.2006.PubMed CentralView ArticlePubMedGoogle Scholar
- Kevin LG, Steemers FJ, Lee G, Mendoza LG, Chee MS: A genome-wide scalable SNP genotyping assay using microarray technology. Nature Genet. 2005, 37: 549-554. 10.1038/ng1547.View ArticleGoogle Scholar
- Refour P, Gissot M, Siau A, Mazier D, Vaquero C: Vers une utilisation des bio-puces à ADN dans l'étude des isolats de Plasmodium falciparum de terrain. Med Trop. 2004, 64: 387-393.Google Scholar
- World Health Organization: World Malaria Report. 2008Google Scholar
- Gay-Andrieu F, Adehossi E, Lacroix V, Gagara M, Ibrahim ML, Kourna H, Boureima H: Epidemiological, clinical and biological features of malaria among children in Niamey, Niger. Malar J. 2005, 4: 10-10.1186/1475-2875-4-10.PubMed CentralView ArticlePubMedGoogle Scholar
- Dugelay F, Adehossi E, Adamou S, Ousmane I, Parzy D, Delmont J, Parola P: Efficacy of chloroquine in the treatment of uncomplicated, Plasmodium falciparum malaria in Niamey, Niger, in 2001. Ann Trop Med Parasitol. 2003, 97: 83-86. 10.1179/00349803125002760.View ArticlePubMedGoogle Scholar
- Ibrahim ML, Gay-Andrieu F, Adehossi E, Lacroix V, Randrianarivelojosia M, Duchemin JB: Field-based evidence for the linkage of pfcrt and pfdhfr drug-resistant malaria genotypes and clinical profiles for severe malaria in Niger. Microbes Infect. 2007, 9: 599-604. 10.1016/j.micinf.2007.02.003.View ArticlePubMedGoogle Scholar
- Ibrahim ML, Hassane H, Konate L, Adamou S, Ousmane I, Adehossi E, Jeanne I, Duchemin JB: Réseau de surveillance moléculaire de la chimiorésistance de Plasmoium falciparum à la chloroquine et la pyriméthamine dans la vallée du fleuve Niger, au Niger. Bull Soc Path Exot. 2008, 101: 47-49.Google Scholar
- Crameri A, Marfurt J, Mugittu K, Maire N, Regös A, Coppee JY, Sismeiro O, Burki R, Huber E, Laubscher D, Puijalon O, Genton B, Felger I, Beck HP: Rapid microarray-based method for monitoring of all currently known single nucleotide polymorphisms associated with parasite resistance to antimalaria drugs. J Clin Microbiol. 2007, 45: 3685-3991. 10.1128/JCM.01178-07.PubMed CentralView ArticlePubMedGoogle Scholar
- Czeher C, Labbo R, Djibrilla A, Here L, Arzika I, Duchemin JB: ELISA study of oocyst-sporozoite transition in malaria vectors. Parasite. 2006, 13: 257-261.View ArticlePubMedGoogle Scholar
- Steenkeste N, Dillies M-A, Khim N, Sismeiro O, Chy S, Lim P, Crameri A, Bouchier C, Imwong M, Rogier C, Coppee J-Y, Ariey A: Flexichip package: an universal microarray with a dedicated analysis software for high-thoughput SNPs detection linked to antimalaria drug resistance.Google Scholar
- Ariey F, Duchemin JB, Robert V: Metapopulation concepts applied to falciparum malaria and their impacts on the emergence and spread of chloroquine resistance. Infect Genet Evol. 2003, 2: 185-192. 10.1016/S1567-1348(02)00099-0.View ArticlePubMedGoogle Scholar
- Hasting IM: Malaria control and evolution of drug resistance: an intriguing ling. Trends Parasitol. 2003, 19: 70-73. 10.1016/S1471-4922(02)00017-X.View ArticleGoogle Scholar
- White NJ: Antimalarial drug resistance. J Clin Invest. 2004, 113: 1084-92.PubMed CentralView ArticlePubMedGoogle Scholar
- Mackinnon M, Read A: Virulence in malaria: an evolutionary viewpoint. Philos Trans R Soc Lond B Biol Sci. 2004, 359: 965-986. 10.1098/rstb.2003.1414.PubMed CentralView ArticlePubMedGoogle Scholar
- Talisuna AO, Erhart A, Samarasinghe S, Van Overmeir C, Speybroeck N, D'Alessandro U: Malaria transmission intensity and the rate of spread of chloroquine resistant Plasmodium falciparum: Why have theorical models generated conflicting results?. Infect Genet Evol. 2006, 6: 241-248. 10.1016/j.meegid.2005.06.003.View ArticlePubMedGoogle Scholar
- Diallo DA, Sutherland C, Nebié I, Konaté AT, Ord R, Pota H, Roper C, Ilboudo-Sanogo E, Greenwood BM, Cousens SN: Sustained use of insecticide-treated curtains is not associated with greater circulation of drug-resistant malaria parasites, or with higher risk of treatment failure among children with uncomplicated malaria in Burkina Faso. Am J Trop Med Hyg. 2007, 76: 237-244.PubMedGoogle Scholar
- Ibrahim ML, Kim N, Hadiza HA, Ariey F, Duchemin JB: Polymorphism of PfATPase6 in Niger: detection of tree new point mutations. Malar J. 8 (1): 28-Google Scholar
- Walliker D, Hunt P, Babiker H: Fitness of drug-resistant malaria parasites. Acta Trop. 2005, 94: 251-259.View ArticlePubMedGoogle Scholar
- Ariey F, Robert V: The puzzling links between malaria transmission and drug resistance. Trends Parasitol. 2003, 19: 158-160. 10.1016/S1471-4922(03)00054-0.View ArticlePubMedGoogle Scholar
- Alifrangis M, Lemnge MM, Rønn AM, Segeja MD, Mageja SM, Khalil IF, Bygbjerg IC: Increasing prevalence of wild types in the dihydrofolate reductase gene of Plasmodium falciparum in an area with high levels of sulfadoxine/pyrimethamine resistance after introduction of treated bed nets. Am J Trop Med Hyg. 2003, 69: 238-243.PubMedGoogle Scholar
- Bogreau H, Renaud F, Bouchiba H, Durand P, Assi SB, Henry MC, Garnotel E, Pradines B, Fusai T, Wade B, Adehossi E, Parola P, Kamil MA, Puijalon O, Rogier C: Genetic diversity and structure of African Plasmodium falciparum populations in urban and rural areas. Am J Trop Med Hyg. 2006, 74: 953-959.PubMedGoogle Scholar
- Bogreau H, Bouchiba H, Assi S, Henry MC, Dossou-Yovo J, Carnevale P, Briolant Pradines B, Fusai T, Rogier C: Diversité, multiplicité des infections et résistance aux antipaludiques de Plasmodium falciparum dans un essai contrôle de moustiquaires impregnées d'insecticide en zone de forte endémie. Med Trop. 2006, 66: 436-Google Scholar
- Diallo DA, Sutherland C, Nebié I, Konate AT, Ord R, Ilboudo-Sanogo E, Greenwood BM, Cousens SN: Children in Burkina Faso who are protected by insecticide-treated materials are able to clear drug-resistant parasites better than unprotected children. J Infect Dis. 2007, 196: 138-144. 10.1086/518252.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.